Hard To Treat Diseases, Incorporated Announces: Details of Patent Application Relating to Viral Infections
Tuesday May 2, 8:00 am ET
DELRAY BEACH, FLORIDA--(MARKET WIRE)--May 2, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces the Company's patent application relating to viral infections will be available on the United States Patent and Trademark Office's ("USPTO") website in June 2006.
In December 2004, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Viral Infections. This application provides a novel method for inhibition of viral infections and to the therapeutic treatment of diseases or disorders caused by such viral infections. The application became a utility patent application in December 2005. It will be available by the USPTO in full for review in June 2006 and scheduled for examination.
Two substances listed in the application, Tubercin (T-5) and Specific Substance of Maruyama ("SSM"), were acquired by HTTD for testing. The rights to the composition, Tubercin (T-5), are owned by Dr. Chung of South Korea, the inventor and patent holder. Dr. Chung has licensed the rights to Tubercin (T-5) for the use in medical care of cancer to another party. SSM was developed and advanced by Zeria Pharmaceutical Co., Ltd. ("Zeria") of Japan. This drug was also called Z-100 for clinical trials and is currently trade named Ancer 20. Zeria is currently using Ancer 20 injection for radiotherapy-induced leukopenia. The composition patent for this drug has been abandoned and is no longer protected by patent.
HTTD's CEO, Colm J. King, has met with both Dr. Chung in South Korea and with the President of Zeria USA, Inc. regarding the advancement of HTTD's patent applications.
The above utility application is one of two patent applications currently being packaged for presentation to major drug companies. Pharmaceutical companies that specialize in oncology and infectious diseases are the targeted candidates for the acquisition of HTTD's patent rights, testing and research. Additional testing by HTTD is not required for our presentation, but the Companies medical advisors and researchers have prepared protocols for additional testing that will enhance HTTD's current applications and potentially lead to new patent applications for the treatment of other diseases.
Additional information is available on the Company's website at: www.htdsotc.com and a presentation regarding HTTD by Mr. King is available at the following link: publiccoreport.net |
